Cerecor Inc. Reports First Quarter 2016 Financial Results

BALTIMORE--(BUSINESS WIRE)--Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced its financial results for the first quarter ended March 31, 2016.

“The first quarter was highlighted by our initiation of a Phase 2 study with CERC-501 for smoking cessation,” said Uli Hacksell, President and Chief Executive Officer of Cerecor.
MORE ON THIS TOPIC